The author of a 2006 review article published in Abdominal Imaging has retracted it because it hews too closely to previously published articles.
The review described the latest imaging techniques used in cancer, focusing on genitourinary conditions.
Here’s the full text of the retraction notice for “New Horizons in Genitourinary Oncologic Imaging”:
Continue reading Highly cited cancer researcher pulls review for “similar text and illustrations”
Authors from Xinxiang Medical University in Weihui, China, are retracting a 2014 paper in Molecular Biology Reports because… well, because lots of things.
The researchers exposed nine rats to acute levels of alcohol then compared them to unexposed mice rats, noting differences in gene expression and molecular pathways.
But no one is toasting these findings anymore. Here are the details behind the retraction, courtesy of the notice:
Continue reading Drunk rats paper wasted by “significant statistical errors”, among other issues
Authors of a 2010 Chemistry – A European Journal article have retracted it “due to the wrong assignment of structure” of catalysts.
The retraction is the third, by our count, for corresponding author Doo Ok Jang, a chemist at Yonsei University in Wonju. Jang authored one of the previously retracted papers with Sung Jun Kim and the other with Sang Yoon Kim. Both papers were also sunk by misassigned structures.
The current study, “Enantioselective Radical Addition to Ketimines: A Synthetic Route Towards α,α-Disubstituted α-Amino Acids,” is authored by all three chemists. Here’s the retraction notice:
Continue reading Third structure slip-up for chemist in Korea yields retraction
This is the second article in a series by John R. Thomas, Jr., a lawyer at Gentry Locke [Editor’s note, 3/26/19: He has since moved to Haley, Hafemann, Magee and Thomas] who represents whistleblowers in a variety of False Claims Act cases. In this installment, he writes about how whistleblowers can tell if they have a viable FCA case.
In my first article, I briefly outlined the role that the False Claims Act (FCA) can play in promoting scientific integrity and safeguarding public grant funding. This article will answer a more substantive and practical question that a potential whistleblower must consider: What constitutes a viable FCA case? Continue reading So you want to be a whistleblower? Part II
The authors of a study on the effects of the hormone leptin on the liver have retracted it from Cell Metabolism, almost four months after the Office of Research Integrity (ORI) determined it contained faked data, courtesy of its first author.
However, the authors say that the paper’s conclusions remain valid, and are supported by new experiments and additional research by outside groups.
Here’s more from the retraction notice: Continue reading Authors retract leptin paper due to “fabricated data”
Once again, a team of Duke University scientists has retracted a paper, this time due to “unreliable” figure data.
With co-authors at the U.S. Environmental Protection Agency, the Duke team has withdrawn a paper from the American Journal of Respiratory Cell and Molecular Biology after concern about data in three figures led them to repeat one of their main experiments. They subsequently found “no evidence” supporting their previous conclusion.
By our count, it is the third retraction from a team that includes William Foster, a pulmonary researcher at the Duke Medical Center. The Duke team retracted a paper in 2013 on a related topic—the effect of early life ozone exposure on airways—from the Journal of Applied Physiology when it was discovered that, familiarly, data in a figure were “unreliable”. Recently, they also retracted a PNAS paper on asthma treatment earlier this month, due to missing primary data and mismatched data from two sources.
Continue reading “Unreliable” data suffocates third paper for Duke pulmonary team
Stanley Rapoport, a neuroscientist in the National Institute on Aging, isn’t having a lot of luck with his first authors. One committed misconduct and cost him a paper in the journal Age last year, and now he’s lost another paper with a different first author, but for the exact same reason.
The latest paper, in Neurochemical Research, examined whether chronic doses of aspirin reduce brain inflammation. It has been cited 14 times, according to Thomson Scientific’s Web of Knowledge.
Here’s more from the note: Continue reading NIH neuroscientist loses second paper, again the result of first author misconduct
A University of Minnesota former chemistry graduate student has been banned from receiving federal funding for five years based on “a preponderance of the evidence that the Respondent intentionally and knowingly engaged in research misconduct.”
Venkata J. Reddy appears to have manipulated findings in one R01 grant application. In recent years, bans are less common than having research supervised. What’s also unusual is that the sanction appeared to have begun two years ago, in 2013, because it lifts August 26, 2018. The report, which is scheduled to published tomorrow in the Federal Register, says the debarment has a “joint jurisdiction,” suggesting another agency may be involved. [See first update at end of post.]
According to the ORI notice, Reddy “intentionally and knowingly engaged in research misconduct by falsifying and/or fabricating data that was provided to his mentor” for an R01 application to the National Institute of General Medical Sciences (NIGMS). More specifically: Continue reading Misconduct earns researcher a five-year ban on federal funding
The Egyptian Journal of Anaesthesia is retracting a 2014 paper by a pair of researchers at Cairo University who appear to have tinkered with their protocol after having received ethics approval.
The paper, titled “Can Sugammadex improve the reversal profile of Atracurium under Sevoflurane anesthesia?” was written by Heba Ismail Ahmed Nagy and Hany Wafik Elkadi, both in the department of anesthesiology.
Sugammadex, or Bridion, is given to rapidly reverse the effects of drugs that keep patients motionless during surgery. It is available throughout the world but not, as it happens, in the United States, where the Food and Drug Administration has refused to approve the agent because of fears that it might provoke severe allergic-like reactions.
According to the retraction notice:
Continue reading Drug study pulled after researchers admit altering trial protocol
Three chemists at the Indian Institute of Technology Guwahati in India have retracted a paper from the Journal of Organic Chemistry because the “incorrect files were inadvertently used.”
The article, “Room-Temperature Cu(II)-Catalyzed Chemo- and Regioselective Ortho-Nitration of Arenes via C–H Functionalization,” described a protocol to perform nitration — the addition of nitro groups onto an organic compound — using an inexpensive copper catalyst.
All three authors signed the one-sentence notice:
Continue reading Chem paper fails to catalyze when wrong files are “inadvertently used”